Pharmacological effects of niacin on acute hyperlipemia

Current Medicinal Chemistry

Volumn 23, Issue 25, 2016, Pages 2826-2835

  Montserrat De La Paz, Sergio ^a   Bermudez, Beatriz ^b   Naranjo, M Carmen ^a   Lopez, Sergio ^a   Abia, Rocio ^a   Muriana, Francisco J G ^a  

^a INSTITUTO DE LA GRASA   (Spain)

^b UNIVERSITY OF SEVILLE   (Spain)

Author keywords

Cardiovascular disease; Hyperlipemia; Niacin; Postprandial state; Triglyceride rich lipoproteins; Vitamin B3

Indexed keywords

APOLIPOPROTEIN B48; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; ADENYLATE CYCLASE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; PHOSPHOLIPASE A2;

CARDIOVASCULAR DISEASE; DIET THERAPY; DISEASE COURSE; DRUG MECHANISM; EXERCISE; HUMAN; HYPERLIPIDEMIA; LIFESTYLE MODIFICATION; METABOLISM; PATHOGENESIS; POSTPRANDIAL STATE; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; HYPERLIPIDEMIAS;

ADENYLYL CYCLASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; HUMANS; HYPERLIPIDEMIAS; LIPOPROTEIN(A); NIACIN; PHOSPHOLIPASES A2; TRIGLYCERIDES;

EID: 84983428703     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867323666160411142909     Document Type: Review

References (77)

1. Chapman, M. J.; Ginsberg, H. N.; Amarenco, P.; Andreotti, F.; Boren, J.; Catapano, A. L.; Descamps, O. S.; Fisher, E.; Kovanen, P. T.; Kuivenhoven, J. A.; Lesnik, P.; Masana, L.; Nordestgaard, B. G.; Ray, K. K.; Reiner, Z.; Taskinen, M. R.; Tokgozoglu, L.; Tybjaerg-Hansen, A.; Watts, G. F.; European Atherosclerosis Society Consensus Panel. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur. Heart J., 2011, 32, 1345-1361.
2. Zeman, M.; Vecka, M.; Perlik, F.; Hromadka, R.; Stankova, B.; Tvrzicka, E.; Zak, A. Niacin in the treatment of hyperlipidemias in light of new clinical trials: has niacin lost its place?. Med. Sci. Monit., 2015, 21, 2156-2162.
3. Kearny, P. M.; Blackwell, L.; Collins, R.; Keech, A.; Simes, J.; Peto, R.; Armitage, J.; Baigent, C. Efficacy of cholesterol-lowering therapy in 18686 people with diabetes in 14 randomised trials of statins: A meta-analysis. Lancet, 2008, 371, 117-125.
4. Song, W. L.; FitzGerald, G. A. Niacin, an old drug with a new twist. J. Lipid Res., 2013, 54, 2586-2594.
5. Martin, P. M.; Ananth, S.; Cresci, G.; Roon, P.; Smith, S.; Ganapathy, V. Expression and localization of GPR109A (PUMA-G/HM74A) mRNA and protein in mammalian retinal pigment epithelium. Mol. Vis., 2009, 15, 362-372.
6. Varela, L. M.; Ortega-Gomez, A.; Lopez, S.; Abia, R.; Muriana, F. J.; Bermudez, B. The effects of dietary fatty acids on the postprandial triglyceride-rich lipoprotein/apoB48 receptor axis in human monocyte/macrophage cells. J. Nutr. Biochem., 2013, 24, 2031-2039.
7. Bermudez, B.; Lopez, S.; Ortega, A.; Varela, L. M.; Pacheco, Y. M.; Abia, R.; Muriana, F. J. Oleic acid in olive oil: from a metabolic framework toward a clinical perspective. Curr. Pharm. Des., 2011, 17, 831-843.
8. Chan, D. C.; Pang, J.; Romic, G.; Watts, G. F. Postprandial hypertriglyceridemia and cardiovascular disease: Current and future therapies. Curr. Atheroscler. Rep., 2013, 15, 309-317.
9. Cohn, J. S. Postprandial lipemia and remnant lipoproteins. Clin. Lab. Med., 2006, 26, 773-786.
10. Zilversmit, D. B. Atherogenesis: A postprandial phenomenon. Circulation, 1979, 60, 473-485.
11. Sniderman, A. D. Postprandial hypertriglyceridemia(s): Time to enlarge our pathophysiologic perspective. Eur. J. Clin. Invest., 2000, 30, 935-937.
12. Patsch, J. R.; Miesenbock, G.; Hopferwieser, T.; Muhlberger, V.; Knapp, E.; Dunn, J. K.; Gotto, A. M.; Patsch, W. Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. Arterioscler. Thromb., 1992, 12, 1336-1345.
13. Proctor, S. D.; Vine, D. F.; Mamo, J. C. Arterial retention of apolipoprotein B(48)-and B(100)-containing lipoproteins in atherogenesis. Curr. Opin. Lipidol., 2002, 13, 461-470.
14. Pirillo, A.; Norata, G. D.; Catapano, A. L. Postprandial lipemia as a cardiometabolic risk factor. Curr. Med. Res. Opin., 2014, 30, 1489-1503.
15. Patel, S.; Puranik, R.; Nakhla, S.; Lundman, P.; Stocker, R.; Wang, X. S.; Lambert, G.; Rye, K. A.; Nicholls, S. J.; Celermajer, D. S. Acute hypertriglyceridaemia in humans increases the triglyceride content and decreases the antiinflammatory capacity of high density lipoproteins. Atherosclerosis, 2009, 204, 424-428.
16. Lindman, A. S.; Veierod, M. B.; Tverdal, A.; Pedersen, J. L.; Selmer, R. Nonfasting triglycerides and risk of cardiovascular death in men and women from the Norwegian counties study. Eur. J. Epidemiol., 2010, 25, 789-798.
17. Boren, J.; Matikainen, N.; Adiels, M.; Taskinen, M. R. Postprandial hypertriglyceridemia as a coronary risk factor. Clin. Chim. Acta, 2014, 431, 131-142.
18. Miller, M.; Cannon, C. P.; Murphy, S. A.; Qin, J.; Ray, K. K.; Braunwald, E. Impact of triglyceride levels beyond lowdensity lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J. Am. Coll. Cardiol., 2008, 51, 724-730.
19. Nordestgaard, B. G.; Benn, M.; Schnohr, P.; Tybjaerg-Hansen, A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA, 2007, 298, 299-308.
20. Bansal, S.; Buring, J. E.; Rifai, N.; Mora, S.; Sacks, F. M.; Ridker, P. M. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA, 2007, 298, 309-316.
21. Varbo, A.; Benn, M.; Tybjaerg-Hansen, A.; Jorgensen, A. B.; Frikke-Schmidt, R.; Nordestgaard, B. G. Remnant cholesterol as a causal risk factor for ischemic heart disease. J. Am. Coll. Cardiol., 2013, 61, 427-436.
22. Miller, M.; Stone, N. J.; Ballantyne, C.; Bittner, V.; Criqui, M. H.; Ginsberg, H. N.; Goldberg, A. C.; Howard, W. J.; Jacobson, M. S.; Kris-Etherton, P. M.; Lennie, T. A.; Levi, M.; Mazzone, T.; Pennathur, S. Triglycerides and cardiovascular disease. Circulation, 2011, 123, 2292-2333.
23. Catapano, A. L.; Reiner, Z.; De Backer, G.; Graham, I.; Taskinen, M. R.; Wiklund, O.; Agewall, S.; Alegria, E.; Chapman, M.; Durrington, P.; Erdine, S.; Halcox, J.; Hobbs, R.; Kjekshus, J.; Filardi, P. P.; Riccardi, G.; Storey, R. F.; Wood, D.; European Society of Cardiology (ESC); and the European Atherosclerosis Society (EAS). ESC/EAS guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis, 2011, 217, 3-46.
24. Berglund, L.; Brunzell, J. D.; Goldberg, A. C.; Goldberg, I. J.; Sacks, F.; Murad, M. H.; Stalenhoef, A. F.; Endocrine Society. Evaluation and treatment of hypertriglyceridemia: An Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab., 2012, 97, 2969-2989.
25. Watts, G. F.; Ooi, E. M.; Chan, D. C. Demystifying the management of hypertriglyceridaemia. Nat. Rev. Cardiol., 2013, 10, 648-661.
26. Lopez, S.; Bermudez, B.; Ortega, A.; Varela, L. M.; Pacheco, Y. M.; Villar, J.; Abia, R.; Muriana, F. J. Effects of meals rich in either monounsaturated or saturated fat on lipid concentrations and on insulin secretion and action in subjects with high fasting triglyceride concentrations. Am. J. Clin. Nutr., 2011, 93, 494-499.
27. Lopez, S.; Bermudez, B.; Pacheco, Y. M.; Villar, J., Abia, R.; Muriana, F. J. Distinctive postprandial modulation of beta cell function and insulin sensitivity by dietary fats: monounsaturated compared with saturated fatty acids. Am. J. Clin. Nutr., 2008, 88, 638-644.
28. Pacheco, Y. M.; Bermudez, B.; Lopez, S.; Abia, R.; Villar, J.; Muriana, F. J. Ratio of oleic to palmitic acid is a dietary determinant of thrombogenic and fibrinolytic factors during the postprandial state in men. Am J. Clin. Nutr., 2006, 84, 342-349.
29. Task Force Members, Ryden, L.; Grant, P. J.; Anker, S. D.; Berne, C.; Cosentino, F.; Danchin, N.; Deaton, C.; Escaned, J.; Hammes, H. P.; Huikuri, H.; Marre, M.; Marx, N.; Mellbin, L.; Ostergren, J.; Patrono, C.; Seferovic, P.; Uva, M. S.; Taskinen, M. R.; Tendera, M.; Tuomilehto, J.; Valensi, P.; Zamorano, J. L.; ESC Committee for Practice Guidelines (CPG); Zamorano, J. L.; Achenbach, S.; Baumgartner, H.; Bax, J. J.; Bueno, H.; Dean, V.; Deaton, C.; Erol, C.; Fagard, R.; Ferrari, R.; Hasdai, D.; Hoes, A. W.; Kirchhof, P.; Knuuti, J.; Kolh, P.; Lancellotti, P.; Linhart, A.; Nihoyannopoulos, P.; Piepoli, M. F.; Ponikowski, P.; Sirnes, P. A.; Tamargo, J. L.; Tendera, M.; Torbicki, A.; Wijns, W.; Windecker, S.; Document Reviewers; De Backer, G.; Sirnes, P. A; Ezquerra, E. A.; Avogaro, A.; Badimon, L.; Baranova, E.; Baumgartner, H.; Betteridge, J.; Ceriello, A.; Fagard, R.; Funck-Brentano, C.; Gulba, D. C.; Hasdai, D.; Hoes, A. W.; Kjekshus, J. K.; Knuuti, J.; Kolh, P.; Lev, E.; Mueller, C.; Neyses, L.; Nilsson, P. M.; Perk, J.; Ponikowski, P.; Reiner, Z.; Sattar, N.; Schachinger, V.; Scheen, A.; Schirmer, H.; Stromberg, A.; Sudzhaeva, S.; Tamargo, J. L.; Viigimaa, M.; Vlachopoulos, C.; Xuereb, R. G. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur. Heart J., 2013, 34, 3035-3087.
30. Kolovou, G. D.; Mikhailidis, D. P.; Kovar, J.; Lairon, D.; Nordestgaard, B. G.; Ooi, T. C.; Perez-Martinez, P.; Bilianou, H.; Anagnostopoulou, K.; Panotopoulos, G. Assessment and clinical relevance of non-fasting and postprandial triglycerides: An expert panel statement. Curr. Vasc. Pharmacol., 2011, 9, 258-270.
31. Tremblay, A. J.; Lamarche, B.; Hogue, J. C.; Couture, P. Effects of ezetimibe and simvastatin on apolipoprotein B metabolism in males with mixed hyperlipidemia. J. Lipid Res., 2009, 50, 1463-1471.
32. Chan, D. C.; Wong, A. T.; Yamashita, S.; Watts, G. F. Apolipoprotein B-48 as a determinant of endothelial function in obese subjects with type 2 diabetes mellitus: effect of fenofibrate treatment. Atherosclerosis, 2012, 221, 484-489.
33. Liu, D.; Wang, X.; Kong, L.; Chen, Z. Nicotinic acid regulates glucose and lipi metabolism through lipid independent pathways. Curr. Pharm. Biotechnol., 2015, 16, 3-10.
34. Altschul, R.; Hoffer, A.; Stephen, J. D. Influence of nicotinic acid on serum cholesterol in man. Arch. Biochem. Biophys., 1955, 54, 558-559.
35. Vosper, H. Niacin: A re-emerging pharmaceutical for the treatment of dyslipidaemia. Br. J. Pharmacol., 2009, 158, 429-441.
36. Canner, P. L.; Berger, K. G.; Wenger, N. K.; Stamler, J.; Friedman, L.; Prineas, R. J.; Friedeswald, W. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J. Am. Coll. Cardiol., 1986, 8, 1245-1255.
37. Anonymous. Clofibrate and niacin in coronary heart disease. JAMA, 1975, 231, 360-381.
38. Rhodes, T.; Norquist, J. M.; Sisk, C. M.; McQuarrie, K.; Trovato, A.; Liao, J.; Maccubbin, D.; Watson, D. J. The association of flushing bother, impact, treatment satisfaction and discontinuation of niacin therapy. Int. J. Clin. Pract., 2013, 67, 1238-1246.
39. Ma, L.; Lee, B. H.; Mao, R.; Cai, A.; Jia, Y.; Clifton, H.; Schaefer, S.; Xu, L.; Zheng, J. Nicotinic acid activates the capsaicin receptor TRPV1. Potential mechanism for cutaneous flushing. Arterioscler. Thromb. Vasc. Biol., 2014, 34, 1272-1280.
40. Clifton, H. L.; Inceoglu, B.; Ma, L.; Zheng, J.; Schaefer, S. TRPV1 channels are involved in niacin-induced cutaneous vasodilation in mice. J. Cardiovasc. Pharmacol., 2015, 65, 184-191.
41. Ma, L.; Lee, B. H.; Clifton, H.; Schaefer, S.; Zheng, J. Nicotinic acid is a common regulator of heat-sensing TRPV1-4 ion channels. Sci. Rep., 2015, 5, 8906.
42. Cooper, D. L.; Murrell, D. E.; Roane, D. S.; Harirforoosh, S. Effects of formulation design on niacin therapeutics: mechanism of action, metabolism, and drug delivery. Int. J. Pharm., 2015, 490, 55-64.
43. Cooper, D. L.; Carmical, J. A.; Panus, P. C.; Harirforoosh, S. Formulation and in vitro evaluation of niacin-loaded nanoparticles to reduce prostaglandin mediated vasodilatory flushing. Eur. Rev. Med. Pharmacol. Sci., 2015, 19, 3977-3988.
44. Creider, J. C.; Hegele, R. A.; Joy, T. R. Niacin: Another look at underutilized lipid-lowering medication. Nat. Rev. Endocrinol., 2012, 8, 517-528.
45. Carlson, L. A.; Danielson, M.; Ekberg, I.; Klintermar, B.; Rosenhamer, G. Atherosclerosis. Reduction of myocardial reinfarction by the combined treatment with clofibrate and nicotinic acid. Atherosclerosis, 1977, 28, 81-86.
46. Blankenhorm, D. H.; Nessim, S. A.; Johnson, R. L.; Sanmarco, M. E.; Azen, S. P.; Cashin-Hemphill, L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA, 1987, 257, 3233-3240.
47. Brown, B. G.; Zhao, X. Q.; Chait, A.; Fisher, L. D.; Cheung, M. C.; Morse, J. S.; Dowdy, A. A.; Marino, E. K.; Bolson, E. L.; Alaupovic, P.; Frohlich, J.; Albers, J. J. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med., 2001, 345, 1583-1589.
48. Taylor, A. J.; Sullenberger, L. E.; Lee, H. J.; Grace, K. A. Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2: A double-blind, placebo-controlled study of extended release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation, 2004, 110, 3512-3517.
49. Taylor, A. J.; Villines, T. C.; Stanek, E. J.; Devine, P. J.; Griffen, L.; Miller, M.; Weissman, N. J.; Turco, M. Extended-release niacin or ezetimibe and carotid intima-media thickness. N. Engl. J. Med., 2009, 361, 2113-2122.
50. Whitney, E. J.; Krasuski, R. A.; Personius, B. E.; Michalek, J. E.; Maranian, A. M.; Kolasa, M. W.; Monick, E.; Brown, B. G.; Gotto, A. M. Jr. Randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effect on progression of coronary heart disease and clinical events. Ann. Intern. Med., 2005, 142, 95-104.
51. Boden, W. E.; Probstfield, I. L.; Anderson, T.; Chaitman, B. R.; Desvignes-Nickens, P.; Koprowicz, K.; McBride, R.; Teo, K.; Weintraub, W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med., 2011, 365, 2255-2267.
52. HPS2-THRIVE Collaborative Group, Landray, M. J.; Haynes, R.; Hopewell, J. C.; Parish, S.; Aung, T.; Tomson, J.; Wallendszus, K.; Craig, M.; Jiang, L.; Collins, R.; Armitage, J. Effects of extended-release niacin with laropiprant in high-risk patients. N. Engl. J. Med., 2014, 371, 203-212.
53. Anderson, T. J.; Boden, W. E.; Desvigne-Nickens, P.; Fleg, J. L.; Kashyap, M. L.; McBride, R.; Probstfield, J. L.; AIMHIGH Investigators. Safety profile of extended-release niacin in the AIM-HIGH trial. N. Engl. J. Med., 2014, 371, 288-290.
54. Offermanns, S.; Colletti, S. L.; Lovenberg, T. W.; Semple, G.; Wise, A.; IJzerman, A. P. International Union of Basic and Clinical Pharmacology. LXXXII: nomenclature and classification of hydroxy-carboxylic acid receptors (GPR81, GPR109A, and GPR109B). Pharmacol. Rev., 2011, 63, 269-290.
55. Yasuda, D.; Imura, Y.; Ishii, S.; Shimizu, T.; Nakamura, M. The atypical N-glycosylation motif, Asn-Cys-Cys, in human GPR109A is required for normal cell surface expression and intracellular signaling. FASEB J., 2015, 29, 2412-2422.
56. Lukasova, M.; Hanson, J.; Tunaru, S.; Offermanns, S. Nicotinic acid (niacin): new lipid-independent mechanisms of action and therapeutic potentials. Trends Pharmacol. Sci., 2011, 32, 700-707.
57. Linke, A.; Sonnabend, M.; Fasshauer, M.; Hollriegel, R.; Schuler, G.; Niebauer, J.; Stumvoll, M.; Bluher, M. Effects of extended-release niacin on lipid profile and adipocyte biology in patients with impaired glucose tolerance. Atherosclerosis, 2009, 205, 207-213.
58. Barroso, E.; Rodriguez-Calvo, R.; Serrano-Marco, L.; Astudillo, A. M.; Balsinde, J.; Palomer, X.; Vazquez-Carrera, M. The PPAR'/' activator GW501516 prevents the downregulation of AMPK caused by a high-fat diet in liver and amplifies the PGC-1'-lipin 1-PPAR' pathway leading to increased fatty acid oxidation. Endocrinology, 2011, 152, 1848-59.
59. Kamanna, V. S.; Ganji, S. H.; Kashyap, M. L. Recent advances in niacin and lipid metabolism. Curr. Opin. Lipidol., 2013, 24, 239-245.
60. Le Bloc-h, J.; Leray, V.; Chetiveaux, M.; Freuchet, B.; Magot, T.; Krempf, M.; Nguyen, P.; Ouguerram, K. Nicotinic acid decreases apolipoprotein B100-containing lipoprotein levels by reducing hepatic very low density lipoprotein secretion through a possible diacylglycerol acyltransferase 2 inhibition in obese dogs. J. Pharmacol. Exp. Ther., 2010, 334, 583-589.
61. Riedel, A.; Lang, R.; Rohm, B.; Rubach, M.; Hofmann, T.; Somoza, V. Structure-dependent effects of pyridine derivatives on mechanisms of intestinal fatty acid uptake: regulation of nicotinic acid receptor and fatty acid transporter expression. J. Nutr. Biochem., 2014, 25, 750-757.
62. Navab, M.; Yu, R.; Gharavi, N.; Huang, W.; Ezra, N.; Lotfizadeh, A.; Anantharamaiah, G. M.; Alipour, N.; Van Lenten, B. J.; Reddy, S. T.; Marelli, D. High-density lipoprotein: Antioxidant and anti-inflammatory properties. Curr. Atheroscler. Rep., 2007, 9, 244-248.
63. Vega, G. L.; Grundy, S. M. Lipoprotein responses to treatment with lovastatin, gemfibrozil, and nicotinic acid in normolipidemic patients with hypoalphalipoproteinemia. Arch. Intern. Med., 1994, 154, 73-82.
64. Lamon-Fava, S.; Diffenderfer, M. R.; Barrett, P. H. R.; Buchsbaum, A.; Nyaku, M.; Horvath, K. V.; Asztalos, B. F.; Otokozawa, S.; Ai, M.; Matthan, N. R.; Lichtenstein, A. H.; Dolnikowski, G. G.; Schaefer, E. J. Extended-release niacin alters the metabolism of plasma apolipoprotein (apo) A-I and apoB-containing lipoproteins. Arterioscler. Thromb. Vasc. Biol., 2008, 28, 1672-1678.
65. van der Hoorn, J. W.; de Haan, W.; Berbee, J. F.; Havekes, L. M.; Jukema, J. W.; Rensen, P. C.; Princen, H. M. Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE 3 Leiden. CETP mice. Arterioscler. Thromb. Vasc. Biol., 2008, 28, 2016-2022.
66. Zhang, L. H.; Kamanna, V. S.; Zhang, M. C.; Kashyap, M. L. Niacin inhibits surface expression of ATP synthase beta chain in HepG2 cells: implications for raising HDL. J. Lipid Res., 2008, 49, 1195-1201.
67. Pang, J.; Chan, D. C.; Hamilton, S. J.; Tenneti, V. S.; Watts, G. F.; Barrett, P. H. Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus. Arterioscler. Thromb. Vasc. Biol., 2014, 34, 427-432.
68. Wu, Z. H.; Zhao, S. P. Niacin promotes cholesterol efflux through stimulation of the PPARgamma-LXRalpha-ABCA1 pathway in 3T3-L1 adipocytes. Pharmacology, 2009, 84, 282-287.
69. King, J.; Crouse, J.; Terry, J.; Morgan, T.; Spray, B.; Miller, N. Evaluation of effects of unmodified niacin on fasting and postprandial plasma lipids in normolipidemic men with hypoalphalipoproteinemia. Am. J. Med., 1994, 97, 323-331.
70. O-Keefe, J.; Harris, W.; Nelson, J.; Windsor, S. Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemia. Am. J. Cardiol., 1995, 76, 480-484.
71. Carlson, L. A.; Oro, L.; Ostman, J. Effect of nicotinic acid on plasma lipids in patients with hyperlipoproteinemia during the first week of treatment. J. Atheroscler. Res., 1968, 8, 667-677.
72. Usman, M. H. U.; Qamar, A.; Gadi, R.; Lilly, S.; Goel, H.; Hampson, J.; Mucksavage, M. L.; Nathanson, G. A.; Rader, D. J.; Dunbar, R. L. Extended-release niacin acutely suppresses postprandial triglyceridemia. Am. J. Med., 2012, 125, 1026-1035.
73. Tentolouris, N.; Stylianou, A.; Lourida, E.; Perrea, D.; Kyriaki, D.; Papavasiliou, E. C.; Tselepis, A. D. High postprandial triglyceridemia in patients with type 2 diabetes and microalbuminuria. J. Lipid Res., 2007, 48, 218-225.
74. Ooi, E. M.; Watts, G. F.; Chan, D. C.; Pang, J.; Tenneti, V. S.; Hamilton, S. J.; McCormick, S. P.; Marcovina, S. M.; Barrett, H. R. Effects of extended-release niacin on postprandial metabolism of Lp(a) and ApoB-100-containing lipoproteins in statin-treated men with type 2 diabetes mellitus. Arterioscler. Thromb. Vasc. Biol., 2015, 35(12), 2686-2693. DOI: 10. 1161/ ATVBAHA. 115. 306136
75. Plaisance, E. P.; Mestek, M. L.; Mahurin, A. J.; Taylor, J. K.; Moncada-Jimenez, J.; Grandjean, P. W. Postprandial triglyceride responses to aerobic exercise and extended-release niacin. Am. J. Clin. Nutr., 2008, 88, 30-37.
76. Lusis, A. J.; Attie, A. D.; Reue, K. Metabolic syndrome: from epidemiology to systems biology. Nat. Rev. Genet., 2008, 9, 819-830.
77. Jin, F. Y.; Kamanna, V. S.; Kashyap, M. L. Niacin accelerates intracellular apoB degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (HepG2) cells. Arterioscler. Thromb. Vasc. Biol., 1999, 1051-1059.